Tigris Pharmaceuticals, a drug development company, has initiated dosing in a Phase I clinical trial of GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I that induces apoptosis by
The agreement provides Novotech with the rights to sell in most Middle Eastern countries, all North African countries, India, Pakistan and certain other Asian countries. Sales will be
PhotoThera, a developer of transcranial laser therapy, has closed a $50m series D round of financing led by Warburg Pincus, a private equity firm, to fund a planned
Via Pharmaceuticals, a biotechnology company, has reported encouraging results of a sub-study of patients in its acute coronary syndrome Phase II trial who received serial 64 slice multidetector
Warner Chilcott, a Bermuda-based specialty pharmaceutical company, has reported that one of its subsidiaries and Mayne Pharma International, have filed a second lawsuit against Mylan Pharmaceuticals Inc and
Axentis Pharma has received the orphan drug designation for its lead product candidate Fluidosomes-tobramycin from the Office of Orphan Products Development of the FDA. According to Axentis, this
Mr O’Holla has an extensive background in the fields of R&D, quality, policy development and compliance, which uniquely position him for the dynamic needs of Nfocus and its
Allergan has reported net earnings attributable to shareholders of $44.7 million, or $0.15 per share, for the quarter ended March 31, 2009, compared to $107.7 million, or $0.35
The overall objective of this grant is to generate tools useful in applying ACTCellerate technology to the manufacture of patient-specific therapeutic products. The new grant funds awarded by
According to I-Flow, this patent covers intellectual property for the infusion apparatus used in the company’s flagship ON-Q Pain Relief System and is also used as the basis
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.